A Randomized Controlled Study for Yuanhu Zhitong Dropping Pills in the Treatment of Knee Osteoarthritis

注册号:

Registration number:

ITMCTR1900002490

最近更新日期:

Date of Last Refreshed on:

2019-07-23

注册时间:

Date of Registration:

2019-07-23

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

元胡止痛滴丸治疗膝关节骨性关节炎的随机对照研究

Public title:

A Randomized Controlled Study for Yuanhu Zhitong Dropping Pills in the Treatment of Knee Osteoarthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

元胡止痛滴丸治疗膝关节骨性关节炎的随机对照研究

Scientific title:

A Randomized Controlled Study for Yuanhu Zhitong Dropping Pills in the Treatment of Knee Osteoarthritis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900024712 ; ChiMCTR1900002490

申请注册联系人:

宋学文

研究负责人:

谢兴文

Applicant:

Song Xuewen

Study leader:

Xie Xingwen

申请注册联系人电话:

Applicant telephone:

+86 17693215829

研究负责人电话:

Study leader's telephone:

+86 15002591615

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1073248654@qq.com

研究负责人电子邮件:

Study leader's E-mail:

827975272@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

甘肃省兰州市七里河区瓜州路418号

研究负责人通讯地址:

甘肃省兰州市七里河区瓜州路418号

Applicant address:

418 Guazhou Road, Qilihe District, Lanzhou, Gansu

Study leader's address:

418 Guazhou Road, Qilihe District, Lanzhou, Gansu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

甘肃省中医药研究院

Applicant's institution:

Gansu Institute of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2019-057-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

甘肃省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Gansu Traditional Chinese Medicine Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2019/7/12 0:00:00

伦理委员会联系人:

李玉梅

Contact Name of the ethic committee:

Li Yumei

伦理委员会联系地址:

甘肃省兰州市七里河区瓜州路418号

Contact Address of the ethic committee:

418 Guazhou Road, Qilihe District, Lanzhou, Gansu

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

甘肃省中医药研究院

Primary sponsor:

Gansu Institute of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

甘肃省兰州市七里河区瓜州路418号

Primary sponsor's address:

418 Guazhou Road, Qilihe District, Lanzhou, Gansu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

甘肃省

市(区县):

兰州市

Country:

China

Province:

Gansu

City:

Lanzhou

单位(医院):

甘肃省中医药研究院

具体地址:

七里河区瓜州路418号

Institution
hospital:

Gansu Institute of Traditional Chinese Medicine

Address:

418 Guazhou Road, Qilihe District

经费或物资来源:

甘肃陇神戎发药业股份有限公司

Source(s) of funding:

Gansu Longshen Rongfa Pharmaceutical Co., Ltd.

研究疾病:

膝骨性关节炎

研究疾病代码:

Target disease:

Knee osteoarthritis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

上市后药物

Post-marketing clinical trial

研究目的:

评估元胡止痛滴丸治疗Ⅰ期、Ⅱ期和Ⅲ期早期(膝骨关节炎X线片分期)膝骨性关节炎的疼痛及不良反应症状观察。

Objectives of Study:

To evaluate the effect of Yuanhu Zhitong Dropping Pills on pain and adverse reactions of knee osteoarthritis in stage I, II and III (X-ray staging of knee osteoarthritis).

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合膝关节骨性关节炎的诊断标准; (2)年龄40到75岁; (3)视觉模拟评分法(VAS)大于10mm且小于60mm; (4)参照X线片上的表现,纳入病变为第一期、第二期及第三期早期; (5)过去2周内没有接受过任何药物治疗。

Inclusion criteria

(1) To meet the diagnostic criteria of knee osteoarthritis; (2) Aged 40 to 75 years; (3) Visual analogue scale (VAS) was greater than 10 mm and less than 60 mm. (4) According to the X-ray findings, the lesions included in the first stage, the second stage and the early stage of the third stage. (5) No medication has been taken in the past two weeks.

排除标准:

(1)过去接受过膝关节手术治疗者; (2)患有创伤性骨性关节炎者; (3)孕妇、哺乳期妇女; (4)在一个月内无法参加随访者; (5)合并肝、肾、造血系统、消化系统、心脑血管等严重原发性疾病; (6)患有膝关节结核、膝关节畸形、恶性肿瘤者; (7)患有精神类疾病,不能参与配合者; (8)有阿片类镇痛药、镇静催眠药及酒精滥用史者; (9)对试验药物有过敏史者。

Exclusion criteria:

(1) Those who had received knee surgery in the past; (2) Patients with traumatic osteoarthritis; (3) Pregnant women and lactating women; (4) Those who are unable to attend the follow-up within one month; (5) Complicated with liver, kidney, hematopoietic system, digestive system, cardiovascular and cerebrovascular diseases and other serious primary diseases; (6) Patients with tuberculosis of knee joint, deformity of knee joint and malignant tumors of knee joint; (7) Those who suffer from psychiatric diseases and cannot participate in cooperation; (8) Those with history of opioid analgesics, sedatives and hypnotics and alcohol abuse; (9) those who have a history of allergy to experimental drugs

研究实施时间:

Study execute time:

From 2019-08-01

To      2020-03-31

征募观察对象时间:

Recruiting time:

From 2019-08-01

To      2020-03-31

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

control group

Sample size:

干预措施:

双氯芬酸钠缓释胶囊

干预措施代码:

Intervention:

Diclofenac Sodium Sustained Release Capsules

Intervention code:

组别:

试验组

样本量:

30

Group:

experimental group

Sample size:

干预措施:

元胡止痛滴丸

干预措施代码:

Intervention:

Yuanhu Zhitong Dropping Pills

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

甘肃

市(区县):

兰州

Country:

China

Province:

Gansu

City:

Lanzhou

单位(医院):

甘肃省中医院

单位级别:

三级甲等

Institution/hospital:

Gansu Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

VAS评分

指标类型:

主要指标

Outcome:

VAS score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 40
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表法 宋学文医师:请补充说明何人使用随机数字表产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random Number Table Method.

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心(http://www.chictr.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

China Registry of Clinical Trials (http://www.chictr.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(CRF)和电子采集和管理系统(EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form (CRF) and Electronic Collection and Management System (EDC)

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above